Tag Archives: A1C control

What can the QBSafe trial teach us about person-centered diabetes care? Explore its findings on A1C, medication adherence, and patient priorities.

Improving hemoglobin A1C has long been considered the gold standard in diabetes care. However, many clinicians now question whether lower numbers always translate into healthier, happier patients. The growing debate over how A1C levels relate to real-world diabetes outcomes highlights an important issue in modern medicine: a patient can achieve …

Prioritizing diabetes visits has become essential as clinical care grows more complex and time-limited. With new medications, tighter guidelines, and multiple comorbidities, clinicians often feel like they are solving a puzzle against the clock. So how can you make every minute count without sacrificing care quality? This guide breaks down …

What does success really look like with GLP-1 therapy in 2026? Is it simply lowering A1C, or are clinicians now aiming for something more sustainable like remission or long-term maintenance? As GLP-1 receptor agonists continue to transform diabetes care, the conversation is shifting beyond short-term outcomes. Today, defining clear and …

GLP-1 receptor agonists have transformed type 2 diabetes care. Yet for many patients, gastrointestinal side effects from GLP-1 therapy, such as nausea, vomiting, and constipation, can threaten long-term adherence. Have you ever had a patient achieve an impressive A1C reduction but consider stopping therapy because of persistent nausea? You are …

As more patients succeed on GLP-1 therapy, conversations about tapering these medications are becoming increasingly common in metabolic care. When patients reach meaningful goals in weight reduction, A1C improvement, or cardiometabolic risk, clinicians naturally begin asking what comes next. Is it safe to stop treatment? More importantly, can progress be …